Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aligos TherapeuticsALGS -3.71%44 3-Year EPS without NRI Growth Rate is 49.50% as of Jun. 2026, which is 7% above its 10-year median of 46.10. GuruFocus rates ALGS with a GF Score™ of 44/100 and a GF Value™ of $34.33 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,160 Biotechnology companies, Aligos Therapeutics ranks better than 84.57% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 49.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 49.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Aligos Therapeutics was 50.20% per year. The lowest was 1.90% per year. And the median was 46.10% per year.
Aligos Therapeutics (NAS:ALGS) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Aligos Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
ALGS vs CRVO, PVCT, PSTV: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Aligos Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Aligos Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 49.50% mean?
Aligos Therapeutics (ALGS) has a 3-Year EPS without NRI Growth Rate of 49.50% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aligos Therapeutics and its competitors. This is near median its historical median of 46.10. Over the past decade, Aligos Therapeutics' 3-Year EPS without NRI Growth Rate has ranged from 1.90 to 50.20. According to the industry distribution chart, Aligos Therapeutics ranks #179 out of 1160 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Aligos Therapeutics' 3-Year EPS without NRI Growth Rate too high?
Aligos Therapeutics' current 3-Year EPS without NRI Growth Rate of 49.50% is near median its 10-year median of 46.10. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 50.20. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Aligos Therapeutics' value of 49.50% is 205.6% above this industry median. Based on the distribution chart, Aligos Therapeutics ranks #179 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' 3-Year EPS without NRI Growth Rate compare to CRVO and PVCT?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #179 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places Aligos Therapeutics in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Aligos Therapeutics' value of 49.50% is 205.6% above this benchmark. Historically, Aligos Therapeutics' own 3-Year EPS without NRI Growth Rate has ranged from 1.90 to 50.20 over the past decade. While the company's 10-year median is 46.10 vs. the industry median of 16.20, Aligos Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current 3-Year EPS without NRI Growth Rate of 49.50% is 205.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Aligos Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current 3-Year EPS without NRI Growth Rate is 49.50%, which is near median its own 10-year median of 46.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Possible Value Trap. The stock's GF Value™ is $34.33, compared to a current price of $7.01 — trading 79.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 49.50%, which is near median its 10-year median of 46.10 and 205.6% above the Biotechnology industry median of 16.20. Aligos Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current 3-Year EPS without NRI Growth Rate is 49.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be undervalued.
The current stock price of $7.01 is trading 79.6% below its estimated GF Value™ of $34.33.
GuruFocus considers Aligos Therapeutics to be Possible Value Trap.
Key valuation signals for ALGS:
3-Year EPS without NRI Growth Rate: 49.50% (near median its 10-year median of 46.10)
GF Value™: $34.33 vs. price of $7.01 (79.6% below fair value)
Industry Position: 205.6% above the Biotechnology median (#179 of 1160)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
44GF Score
Get the complete analysis for ALGS
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
